Clinical regulatory writing produces the structured documents health authorities require to evaluate and approve pharmaceutical products. These aren't neutral scientific papers but compliance-focused submissions for FDA, EMA, and other regulators. The work spans protocols, Clinical Study Reports, Investigator's Brochures, informed consent forms, and marketing applications. Quality matters: analysis of 836 protocols found that 57% undergo substantial amendments, with approximately 45% of those classified as avoidable, often due to eligibility criteria or design inconsistencies not fully resolved before finalization. More recent data shows Phase III protocols now average 3.5 substantial amendments, up nearly 60% since 2015. Between 2018 and 2022, 37% of all NDAs and BLAs received Complete Response Letters. ICH E6(R3), finalized in January 2025 and effective in the EU as of July 2025, now emphasizes Quality Management Systems and risk-based approaches. For sites, this means documentation must reflect quality-by-design thinking, with risk assessments and quality tolerance limits visible in trial documents, not buried in operational procedures.